Dr. Accordino on Data From the PEARL Trial in HR+/HER2- Metastatic Breast Cancer

Melissa K. Accordino, MD, MS
Published: Tuesday, Apr 07, 2020



Melissa K. Accordino, MD, MS, assistant professor of medicine, Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the findings of the phase III PEARL trial in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

In the ongoing trial, investigators are comparing the use of the CDK4/6 inhibitor palbociclib plus either exemestane or fulvestrant versus capecitabine (Xeloda) in patients with HR-positive/HER2-negative metastatic breast cancer, says Accordino. Results showed no difference in efficacy with regard to progression-free survival (PFS), but the safety profiles were a bit different, adds Accordino. Among those patients who have already progressed on endocrine therapy, a CDK4/6 inhibitor and endocrine therapy might be a more favorable option over chemotherapy. The time to response was also similar in both arms of the study, which is reassuring, concludes Accordino.
SELECTED
LANGUAGE


Melissa K. Accordino, MD, MS, assistant professor of medicine, Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the findings of the phase III PEARL trial in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

In the ongoing trial, investigators are comparing the use of the CDK4/6 inhibitor palbociclib plus either exemestane or fulvestrant versus capecitabine (Xeloda) in patients with HR-positive/HER2-negative metastatic breast cancer, says Accordino. Results showed no difference in efficacy with regard to progression-free survival (PFS), but the safety profiles were a bit different, adds Accordino. Among those patients who have already progressed on endocrine therapy, a CDK4/6 inhibitor and endocrine therapy might be a more favorable option over chemotherapy. The time to response was also similar in both arms of the study, which is reassuring, concludes Accordino.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x